Group items tagged

The L'Oréal USA For Women in Science fellowship program awards five women postdoctoral scientists annually with grants of $60,000 each for their contributions in Science, Technology, Engineering and Math (STEM) fields and commitment to serving as role models for younger generations. The program is the U.S. component of the L'Oréal-UNESCO For Women in Science International Fellowships program. L'Oréal USA partners with the American Association for the Advancement of Science (AAAS) to manage the program's application and peer-review process. The 2018 L'Oréal USA for Women in Science application period will open December 4th, 2017 and will close on February 2nd, 2018.

As part of this mission, the foundation is seeking applications for scientific research projects with the potential to significantly advance the field toward an effective understanding of the mechanisms of cerebrovascular disease. TAAF grants respond to the cerebrovascular community's need for projects that highlight innovative research strategies that will support the development of novel cerebrovascular therapies, clinical management, and recovery for patients.

This funding opportunity will support a new, centralized infrastructure (U24) to aggregate, harmonize, manage, and share existing and future neuroimaging data collected in NIA-supported Alzheimer's Disease Research Centers (ADRCs). An additional activity will be to define appropriate imaging protocols, as well as assess and anticipate advances in neuroimaging technologies and techniques for inclusion in the standardized protocols to maximize utility for the field of Alzheimer's disease and Alzheimer's disease related dementias (AD/ADRD) research.

This funding opportunity will support a new, centralized infrastructure (U24) to aggregate, harmonize, manage, and share existing and future neuroimaging data collected in NIA- supported Alzheimer's Disease Research Centers (ADRCs).

Reissue of RFA-NS-18-032. The purpose of the NINDS Research Program Award (RPA) is to provide longer-term support and increased flexibility to Program Directors (PDs) /Principal Investigators (PIs) whose records of research achievement demonstrate their ability to make major contributions to neuroscience. RPAs will support the overall research programs of NINDS-funded investigators for up to 8 years, at a level commensurate with a PD/PI's recent NINDS support (Part 2, Section II) This greater funding stability will provide eligible investigators at nearly all career stages increased freedom and flexibility, allowing them to be more adventurous in their research, take greater risks, embark upon research that breaks new ground, undertake research projects that require a longer timeframe, and/or extend previous discoveries in new directions. Research supported through the RPA must be within the scope of the NINDS mission (http://www.ninds.nih.gov/about_ninds/mission.htm). Research activities outside of the NINDS mission, or traditionally supported by another NIH Institute or Center will not be considered through this program. Other anticipated benefits of the RPA include: A more stable funding environment, facilitating the pursuit of longer-term research goals; Flexible funding, enabling investigators to pursue research opportunities as they arise, not tied to specific aims; Reduced time spent writing grant applications and managing multiple grant awards, thereby allowing investigators to spend more time conducting and overseeing research; and More time for PDs/PIsto mentor junior scientists. Eligibility to apply through this FOA is limited to investigators who currently have at least one active NINDS R01 or R01 equivalent grant (defined here as R00, R01, R37, R56, DP1 or DP2 awards), and who have had an active R01 equivalent grant from NINDS in each of the past 5 years, with no more than one of those years in a no cost extension.

"JobsOhio is hosting a town hall meeting to discuss initiatives and strategic assets within the Dayton/Western and Cincinnati/Southwest Ohio region. Join us Thursday, December 17 at 1:30 - 3 p.m. to learn more about our strategy and objectives as well as introduce the advisors and leadership for this sector. JobsOhio's President and CEO, J.P. Nauseef and Managing Director of Military and Federal, Elaine Bryant and will be joined by notable guest speakers who will offer their expertise and alignment on the statewide initiative."

The purpose of this Funding Opportunity Announcement (FOA) is to inform the scientific community of the pain research interests of the various Institutes and Centers (ICs) at the National Institutes of Health (NIH) and to stimulate and foster a wide range of basic, clinical, and translational studies on pain as they relate to the missions of these ICs. New advances are needed in every area of pain research, from the micro perspective of molecular sciences to the macro perspective of behavioral and social sciences. Although great strides have been made in some areas, such as the identification of neural pathways of pain, the experience of pain and the challenge of treatment have remained uniquely individual and unsolved. Furthermore, our understanding of how and why individuals transition to a chronic pain state after an acute injury is limited. Research to address these issues conducted by interdisciplinary and multidisciplinary research teams is strongly encouraged, as is research from underrepresented, minority, disabled, or women investigators.

Applicants must choose one of the following categories they feel their project best exemplifies: 1.) Outstanding Emerging Innovation: The winning nominee is a person or company working on the basic research phase of an innovation - for three years or less, pre-commercialization - that has received grant money or outside money and that demonstrates the potential for continued growth and success. 2.) Outstanding Bioscience Innovation: The winning nominee is a company that has achieved a significant milestone in the life sciences, including but not limited to drug therapeutics, medical devices, medical imaging and pharmacogenetics. 3.) Outstanding Information Technology Innovation: The winning nominee is a company that has achieved a significant milestone in information technology, including hardware and software, packaged applications, custom applications and digital media. 4.) Outstanding Marketing Innovation: The winning nominee is a company that has achieved a significant milestone in consumer marketing. 5.) Outstanding Advanced Engineering Innovation: The winning nominee is a company that has achieved a significant milestone in advanced engineering - where technology is used to design a product.

The Bill & Melinda Gates Foundation is accepting applications for Round 14 of its Grand Challenges Explorations initiative, an accelerated grant program that encourages bold approaches aimed at improving the lives of the world's poorest people. Anyone - students, scientists, entrepreneurs - with a transformative idea is invited to apply.

The University of Chicago is offering talented individuals from traditionally underrepresented populations an expenses-paid opportunity to explore graduate education at the University of Chicago. Join us for a weekend of graduate admissions workshops, presentations by world-renowned faculty and their graduate students, and informal socials. Receive advice on submitting a competitive application to graduate programs and learn how to develop your own career as a scientist, academic, or professional.

The following programs have due dates that fall between October 1 - 25, 2013, and these dates are being revised due to the Federal  government shutdown. These revised dates apply whether the proposal is being submitted via the NSF FastLane System or  Grants.gov. Due to compressed proposal deadlines resulting from the shutdown, proposers are advised that they may experience a  delay when contacting IT Help Central with technical support questions. Frequently asked questions regarding these date changes  are available on the Resumption of Operations page on the NSF website at: http://www.nsf.gov/bfa/dias/policy/postshutdown.jsp. 

The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue translational activities and clinical trials to treat pain with innovative, targeted, and non-addictive diagnostic and/or therapeutic devices that improve patient outcomes and decrease or eliminate the need to prescribe opioids. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, obtaining an Investigational Device Exemption (IDE) for a Significant Risk (SR) study or Institutional Review Board (IRB) approval for a Non-Significant Risk (NSR) study, as well as a subsequent small clinical trial (e.g., Early Feasibility Study). The clinical trial is expected to provide information about the device function or final design that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in the development of the project plan and monitoring of research progress. This FOA will leverage Public-Private Partnership Programs (PPP) initiated under the NIH BRAIN Initiative, the Office of Strategic Coordination The Common Funds Stimulating Peripheral Activity to Relieve Conditions (SPARC) Program, and the HEAL Initiative. These programs include agreements (Memoranda of Understanding, MOU) with a number of device manufacturers willing to make such devices available, including devices and capabilities not yet market approved but appropriate for clinical research. In general, it is expected that the devices' existing safety and utility data will be sufficient to enable new IRB NSR or FDA IDE approval without the need for significant additional non-clinical data.

The purpose of this Funding Opportunity Announcement (FOA) is to support preclinical development and demonstration of safe, effective, and non-addictive device-based technologies and approaches to treat pain. The goal of the program is to demonstrate treatment using credible neural targets for device-based interventions and/or diagnostics for pain, building upon the latest mechanistic knowledge about the anatomy and physiology of central, spinal, and peripheral pathways involved in pain. Awarded activities will facilitate the translation of new devices up to the stage of readiness for first in human (FIH) clinical trials by overcoming key challenges identified during preliminary proof-of-concept studies. The scope of the program includes technology development and optimization, and studies to prepare for approvals for human use. This is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in the development of the project plan and monitoring of research progress.

HEAL Initiative: This is a HEAL Initiative UH3 FOA that will solicit device applications to treat pain.

The purpose of this research is to identify, implement, and evaluate the use of effective strategies and tools for provider and patient use to taper and/or discontinue opioids, benzodiazepines, and other medications in which risk outweighs benefits to prevent falls, overdose, and other injuries among community dwelling older adults.

Multimorbidity, having two or more chronic conditions, is a complex challenge for doctors. This challenge becomes even more complex when treating patients with Alzheimer's disease and related dementia (ADRD), as the clinical presentation and prolonged course of ADRD influence the diagnosis and treatment of comorbid illness. Compared to patients with other long-term disorders, those with dementia may have extreme multimorbidity, averaging four additional chronic medical disorders. The most common chronic comorbid conditions for ADRD patients are hypertension and diabetes, but other significant comorbidities include, but are not limited to, heart disease, heart failure, obstructive lung disease, and incontinence, as well as acute conditions like infectious diseases and hip fracture.

Once established, type 1 diabetes (T1D) requires daily insulin administration and episodes of hyperglycemia and hypoglycemia are common. As a result, patients with T1D without adequate control may suffer devastating acute complications such as life-threatening hypoglycemia and ketoacidosis and long term complications including accelerated cardiac and peripheral vascular diseases, nephropathy, retinopathy, neuropathy, amputation and premature death. Studies such as the Diabetes Control and Complications Trial (DCCT) and the UK Prospective Diabetes Study (UKPDS) have shown that long term microvascular and macrovascular complications can be reduced through tight blood glucose control. However, the increased risk of hypoglycemia that is associated with tight control and the limitations of current glucose control technologies make tight control difficult to achieve. Thus, there is a need for tools to help more people with T1D to safely achieve and sustain tight blood glucose control and reduce burden of care.